Q-omics provides the consensus-scored SMARCD1 profile across patient tissues and cancer cell-line models. SMARCD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMARCD1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SMARCD1 protein abundance shows 22,865 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where SMARCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMARCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMARCD1 survival associations across molecular data types. SMARCD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMARCD1 RNA expression–survival associations across cancer types. High SMARCD1 expression shows unfavorable associations in ACC, MESO, LIHC, KICH and SKCM, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMARCD1 RNA expression.
This table summarizes SMARCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SMARCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMARCD1 shows higher tumor expression in HNSC, COAD, LIHC, STAD, KIRP and BLCA. The HNSC box plot shows higher SMARCD1 RNA expression in tumor versus normal tissue (log2 FC = +1.206, t-test p < 0.001).
This table shows molecular features associated with SMARCD1 in patient tissues and cancer cell lines. In patient samples, SMARCD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMARCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
